Biogen Inc. ( NASDAQ:BIIB – Get Rating ) – Analysts at Wedbush lowered their Q2 2023 earnings estimates for Biogen in a report released on Tuesday, April 25th. Wedbush analyst L. Chico now expects that the biotechnology company will earn $3.28 per share for the quarter, down from their prior forecast of $3.80. Wedbush currently has a 'Neutral' rating and a $263.00 target price on the stock. The consensus estimate for Biogen's current full-year earnings is $15.48 per share. Wedbush also issued estimates for Biogen's Q3 2023 earnings at $4.

https://www.dailypolitical.com/2023/04/29/research-analysts-offer-predictions-for-biogen-inc-s-q2-2023-earnings-nasdaqbiib.html

#dailypolitical